Clinical trials: Prostate Cancer Stage
Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma
Dose Finding Safety Study of VAL201 in Cancer Patients
Dose finding safety study of VAL201 in cancer patients.
- Trial name
- VAL201-001 (NCT02280317)
- Testing
- VAL201
- Volunteers
- 12 people
- Sponsor
- ValiRx Plc
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
This randomized pilot phase I trial will evaluate if quercetin enhances the uptake of green tea polyphenols in the prostate tissue of men taking green tea extract and undergoing radical prostatectomy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01912820
- Testing
- green tea extract, quercetin, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Prostate Cancer, Prostate Cancer Metastatic
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
All patients will be required to have a biopsy of a metastatic tumor deposit at study entry. Pembrolizumab will be administered at a dose of 200 mg as a 30 minute IV infusion every 3 weeks.
- Trial name
- NCT04116775
- Testing
- Fecal microbiota transplant, Pembrolizumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Julie Graff, MD
Prostate Cancer
Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer
The main objectives of this trial are: 1. To assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic CRPC who have not received prior chemotherapy. 2.
- Trial name
- NCT01748500
- Testing
- Pantoprazole
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer Metastatic Castration-Resistant
A Study of KMV002 in Patients With mAPMR Prostate Cancer
This is a first-in-human (FIH) open-label, multicenter, dose-escalation and dose-expansion Phase I study of KMV002 in metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer patients.
- Trial name
- NCT07866300
- Testing
- KMV002
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Chimivac INC
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT04592237
- Testing
- Cabazitaxel, Carboplatin, Cetrelimab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Prostate Cancer
Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer
The aim of this study is to determine the maximum tolerated dose of hypo-fractionated radiation therapy and the toxicity of the treatment program.
- Trial name
- NCT01677845
- Testing
- Radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NYU Langone Health
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Neoplasm
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).
- Trial name
- NCT01630967
- Testing
- Degarelix
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Healthy Male Subjects, Suspected Prostate Cancer
A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer
Phase I/II study in the management of Healthy Male Subjects and patients with suspected prostate cancer.
- Trial name
- NCT06472531
- Testing
- INR101
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Prostatic Neoplasms
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
- Trial name
- NCT00313781
- Testing
- CP-751,871, docetaxel, prednisone
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet…
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT07028853
- Testing
- Mevrometostat, Enzalutamide
- Where
- 319 sites in United States, Argentina and 24 more
- Volunteers
- 1,000 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other…
- Trial name
- NCT07852195
- Testing
- Abiraterone Acetate, Biospecimen Collection, Bone Scan
- Volunteers
- 432 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer
Vidaza to Restore Hormone Thx Prostate
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of…
- Trial name
- NCT00384839
- Testing
- azacitidine for injectable suspension
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Prostate Cancer
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Licorice root extract contains ingredients that may slow the growth of tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- NCT00176631
- Testing
- licorice root extract, docetaxel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer
Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer
This phase II study designed to prospectively evaluate the efficacy and morbidity of IMRT with CyberKnife radiosurgical boosts for clinically localized prostate cancer.
- Trial name
- NCT01618851
- Testing
- Radiotherapy with IMRT and CyberKnife Boost
- Volunteers
- 70 people
- Sponsor
- Georgetown University
Prostate Cancer
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009750
- Testing
- filgrastim, monoclonal antibody m170, cyclosporine
- Where
- United States
- Sponsor
- University of California, Davis
Prostate Cancer
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body.
- Trial name
- NCT04663997
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.